This study is for participants that have been diagnosed with small cell lung cancer, that has spread to the brain. The purpose of this study is to see if high dose radiation therapy delivered only to the small areas of brain cancer and avoiding the surrounding normal brain tissue, called stereotactic radiosurgery (SRS), decrease side effects related to memory and thinking compared to radiation to the entire brain, called, whole-brain radiation therapy (WBRT) that avoids the hippocampus but treats all of the brain tissue along with a drug that helps preserve memory and thinking called memantine. Participants can expect to be on this study for up to 6 months, depending on what treatment they receive (SRS alone or HA-WBRT with memantine). Participants will then be followed every 2 to 3 months for at least 1 year after study completion and then every 6 months for their lifetime or until disease progression.
This study is for patients that have been diagnosed with recurrent or new head and neck squamous cell carcinoma (HNSCC). Patients either have had a recurrence (the tumor has comeback) or a new head and neck cancer in a different area of the head and neck (second primary) which has been removed by surgery. The study drug used is called pembrolizumab. The purpose of this study is to see if adding pembrolizumab to radiation or if using pembrolizumab by itself after surgery compared to the usual approaches with chemotherapy and radiation will increase life expectancy. Participants can expect to be on this study for up to 12 months and then followed for 5 years.
This study is for patients that have been diagnosed with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). The investigational drug used in this study is Debio 1143. The main purpose of this study is to learn how well the study medicine works and how safe the study medicine is compared with placebo. A placebo is an inactive substance that looks like the study medicine but does not contain any active study medicine. Participants can expect to be in this study for up to 7 years. Participation will consist of approximately 56 visits at the study center over a period of 5 years, followed by telephone calls every 6 months over a period of maximum 2 years.
This study is for patients that have been diagnosed with Small-Cell Lung Cancer. The purpose of this study is to find out if this approach is better or worse than the usual approach. The usual approach is defined as care that most people get for small cell lung cancer. Participants can expect to be on this study for two years.
This study is for patients that have been diagnosed with stage III-IVB Head and Neck cancer. The investigational drug in this study is MEDI4736 (Durvalumab). The purpose of the safety lead-in portion of the study is to determine whether adding the study drug MEDI4736 to radiation is safe in patients with head and neck cancer who cannot take the drug cisplatin. The purpose of the phase II/III portion is to compare any good and bad effects of usual radiation plus the study treatment, MEDI4736 (durvalumab), to the usual therapy of radiation plus cetuximab in patients with head and neck cancer who cannot take the drug cisplatin. Participants in the safety lead-in portion can expect to be in this study for approximately 2.5 years. Participants in the Phase II/III portion can expect to be in the study for up to 32 weeks, and then followed by their study doctor to monitor for side effects every year.